Benefits of infusion pump technology in treatment of patients with acquired hemophilia A and hemophilia A with inhibitor a Polish pilot observational study
, 4
Abstract
Introduction: The authors compared the efficacy, practicality and personnel preference of the infusion pump method
against those of bolus administration of rFVIIa.
Material and methods: Three patients with hemophilia A received recombinant factor VIIa infusion pump treatment.
Their hemostasis and response to treatment was strictly monitored. Nursing personnel (n = 20) were surveyed on their
preference and opinion regarding the infusion pump compared to bolus administration of recombinant factor VIIa.
Results: The maintenance of hemostasis was satisfactory in the group of patients who were administered recombinant
factor VIIa via infusion pump, and no dosage was missed or delayed. A large majority of the surveyed personnel
(75%) evaluated the infusion pump as offering a more comfortable and easier administration method than 4-hourly
boluses.
Conclusions: Recombinant factor VIIa via infusion pump is more effective in maintaining hemostasis and is the preferred
administration method among nursing personnel. Patients and personnel alike benefit from infusion pump
administration of recombinant factor VIIa for hemophilia A.
Keywords: haemophilia Aacquired haemophilia Ainhibitorrecombinant factor VIIainfusion pump
References
- Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers. 2021; 7(1): 45.
- Tiede A, Wahler S. The rising incidence of acquired haemophilia A in Germany. Haemophilia. 2021; 27(4): e466–e468.
- Knoebl P, Marco P, Baudo F, et al. EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10(4): 622–631.
- Collins P, Baudo F, Huth-Kühne A, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010; 3: 161.
- Tiangrande P. Acquired hemophilia. Treatment of Hemophilia Series. 2012; 38.
- Windyga J, Baran B, Odnoczko E, et al. Guidelines for the management of acquired hemophilia A in elderly patients. Journal of Transfusion Medicine. 2021; 14(4): 137–155.
- Windyga J, Chojnowski K, Klukowska A, et al. Część II: Wytyczne postępowania w hemofilii A i B powikłanej inhibitorem czynnika VIII i IX (2 wydanie). Acta Haematologica Polonica. 2017; 48(3): 137–159.
- Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2006: 432–437.
- Collins PW, Chalmers E, Hart D, et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from
UKHCDO . British Journal of Haematology. 2013; 162(6): 758–773. - Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013; 4(1): 59–72.
- Marino R. Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies. Medicina (Kaunas). 2023; 59(10).
- Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020; 105(7): 1791–1801.
- Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016; 2016(1): 657–662.
- Charakterystyka Produktu Leczniczego NovoSeven ® z dnia 07. ; 06: 2021.
- Bonde C, Jensen MB. Continuous infusion of recombinant activated factor VII: stability in infusion pump systems. Blood Coagul Fibrinolysis. 1998; 9 Suppl 1: S103–S105.
- Négrier C, Chamouard V, Lienhart A, et al. A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system. Haemophilia. 2019; 25(6): 1020–1027.
- Pollard D, Subel B, Chowdary P, et al. Use of an innovative syringe pump to deliver bolus rFVIIa for patients with haemophilia and inhibitors undergoing surgery. The Journal of Haemophilia Practice. 2018; 4(1): 35–39.
- Schulman S, Bech Jensen M, Varon D, et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost. 1996; 75(3): 432–436.
- Holme PA, Tjønnfjord GE. Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries. Haemophilia. 2019; 25(1): 54–59.
- Stachnik JM, Gabay MP. Continuous infusion of coagulation factor products. Ann Pharmacother. 2002; 36(5): 882–891.
- Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia. 2018; 24(1): 24–32.
- Carlsson M, Berntorp E, Björkman S, et al. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol. 1993; 51(4): 247–252.
- Factor VIII (NovoSeven). The Royal Hospital for Women 2021.
- Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol. 2000; 110(3): 715–720.
- Martinowitz U, Luboshitz J, Bashari D, et al. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia. 2009; 15(3): 676–685.
- Hay CRM, Doughty HI, Savidge GF. Continuous infusion FVIII for surgery and major bleeding. Blood Coagul Fibrinolysis. 1996; 7: 15–19.
- Kempton CL, Soucie JM, Miller CH, et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010; 8(10): 2224–2231.
- von Auer Ch, Oldenburg J, von Depka M, et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci. 2005; 1051: 498–505.
- White B, Cotter M, Byrne M, et al. High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice? Haemophilia. 2000; 6(2): 113–115.
